Filing Flows › Halozyme Therapeutics (HALO) › Recalls, complaints & regulation
Halozyme Therapeutics (HALO): clinical trials
Halozyme Therapeutics (HALO) beyond its filings: 1 active clinical trial.
Halozyme Therapeutics' latest quarter
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Halozyme Therapeutics have?
1 active study on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.